NASDAQ$SIGA
SIGA Technologies, Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
SIGA Technologies' financial performance declined in Q2 2023 compared to Q2 2022, with a decrease in total revenues and a shift from operating income to an operating loss. The company announced significant U.S. government orders for oral and IV TPOXX in July 2023 and anticipates a substantial increase in revenues during the second half of the year.
SIGA Technologies reported a decrease in total revenues and a loss in net income for Q2 2023 compared to Q2 2022. However, the company anticipates a significant increase in revenues during the second half of the year, driven by recent U.S. government orders for oral and IV TPOXX, and expects to achieve full-year 2023 pre-tax operating income between $90 million and $100 million.
- Total revenues decreased to $5.9 million in Q2 2023 from $16.7 million in Q2 2022.
- Operating income shifted to a loss of $4.6 million in Q2 2023, compared to an income of $3.1 million in Q2 2022.
- Net loss was $2.9 million, or $0.04 per share, in Q2 2023, compared to a net income of $2.0 million, or $0.03 per share, in Q2 2022.
- The company expects to generate approximately $113 million of revenues from deliveries of oral TPOXX to the U.S. strategic national stockpile in the second half of 2023.
Headline financials
Revenue & EPS history
SIGA Technologies · Revenue · Quarterly
$5.88M
Revenue by segment
SIGA Technologies · $5.88M total across 2 segments · Q2 2023
- R&D Revenues$4.61M-42.7%78.5%
- Product Sales$1.26M-85.3%21.5%
Forward guidance
SIGA Technologies anticipates a substantial increase in revenues during the second half of 2023, driven by recent U.S. government orders for oral and IV TPOXX, and expects to achieve full-year 2023 pre-tax operating income between $90 million and $100 million.
Tailwinds
- Expected revenues of approximately $113 million from oral TPOXX deliveries to the U.S. strategic national stockpile in the second half of 2023.
- Anticipated revenues between $30 million and $45 million from domestic and international deliveries, including oral TPOXX to the Department of Defense, IV TPOXX to the U.S. strategic national stockpile, and oral TPOXX to international customers.
- Full-year 2023 pre-tax operating income expected to be between $90 million and $100 million.
- Consistent ability to meet demand for oral TPOXX.
- Increasingly diversified global revenue opportunities.
Headwinds
- Risk that BARDA may not exercise all remaining unexercised options under the BARDA Contract.
- Risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms.
- Risk that the BARDA Contract, DoD Contract #2 or PEP Label Expansion R&D Contract are modified or canceled at the request or requirement of the U.S. Government.
- Risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX® internationally.
- Risks associated with actions or uncertainties surrounding the debt ceiling.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+2.4%
Avg return
30 days after
41%
26 / 64 earnings
Positive
+31.9%
Q4 2023
Best reaction
-27.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -5.5% | -8.5% | |
| Q4 2025 | -3.0% | -3.4% | -22.8% | |
| Q3 2025 | -20.2% | -24.0% | -24.1% | |
| Q1 2025 | +4.4% | +9.0% | +10.8% | |
| Q4 2024 | +7.0% | +0.5% | +6.4% | |
| Q3 2024 | -1.9% | -8.5% | -9.8% | |
| Q2 2024 | -12.8% | -14.3% | -9.5% | |
| Q1 2024 | -27.8% | -28.2% | -26.7% | |
| Q4 2023 | +31.9% | +49.9% | +88.3% | |
| Q3 2023 | -4.4% | -2.2% | +16.9% | |
| Q2 2023 | -3.7% | -10.0% | -21.9% | |
| Q1 2023 | +5.1% | +1.8% | -0.7% | |
| Q4 2022 | -3.8% | -7.8% | -13.4% | |
| Q3 2022 | +7.5% | +9.8% | +1.1% | |
| Q2 2022 | +27.4% | +24.6% | -21.0% | |
| Q1 2022 | +3.6% | +4.0% | +60.7% | |
| Q4 2021 | +3.0% | +6.6% | +22.4% | |
| Q3 2021 | -0.7% | +0.0% | +2.8% | |
| Q2 2021 | -2.9% | -4.0% | +9.1% | |
| Q1 2021 | -0.7% | -8.4% | -10.4% | |
| Q4 2020 | +1.7% | +9.3% | +1.2% | |
| Q3 2020 | +2.0% | +3.4% | -0.9% | |
| Q2 2020 | +14.3% | +5.5% | -1.9% | |
| Q1 2020 | -1.4% | +1.4% | +2.9% | |
| Q4 2019 | +10.4% | +0.4% | +0.2% | |
| Q3 2019 | -3.2% | -1.8% | -19.8% | |
| Q2 2019 | +0.2% | -1.7% | +2.7% | |
| Q1 2019 | +1.5% | -1.3% | -12.8% | |
| Q4 2018 | -4.4% | -1.6% | -6.3% | |
| Q3 2018 | +8.4% | +5.7% | +29.1% | |
| Q2 2018 | +0.3% | +7.7% | +1.4% | |
| Q1 2018 | -0.5% | +2.4% | -3.9% | |
| Q4 2017 | -0.6% | -7.0% | -2.3% | |
| Q3 2017 | +2.8% | -1.1% | +3.9% | |
| Q2 2017 | -1.6% | -1.6% | -1.9% | |
| Q1 2017 | -0.3% | +0.6% | -8.0% | |
| Q4 2016 | -0.6% | +0.0% | -4.1% | |
| Q3 2016 | -5.7% | +3.8% | +54.8% | |
| Q2 2016 | +4.5% | +4.1% | +11.4% | |
| Q1 2016 | +1.1% | — | — | |
| Q4 2015 | +1.1% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +5.7% | — | — | |
| Q4 2014 | -1.3% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | -1.4% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q1 2011 | -2.4% | — | — | |
| Q4 2012 | -2.5% | — | — | |
| Q3 2012 | +6.5% | — | — | |
| Q2 2012 | +5.3% | — | — | |
| Q1 2012 | +4.5% | — | — | |
| Q4 2011 | -1.4% | — | — | |
| Q4 2009 | -1.4% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q3 2011 | -6.1% | — | — | |
| Q2 2011 | -12.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q4 2010 | -12.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro